The Cancer Genome Characterization Initiative (CGCI) uses molecular characterization to uncover distinct features of rare cancers. Current projects perform comprehensive molecular cataloging of HIV+ and other rare adult and pediatric cancers. The research community can use CGCI data to gain insights into the underlying mechanisms of these cancers and identify potential therapeutic targets.
CGCI: Cancer Genome Characterization Initiative
News & Publications
The goal of the Burkitt Lymphoma Genome Sequencing Project (BLGSP) is to explore potential genetic changes in patients with Burkitt lymphoma (BL) that could lead to better prevention, detection, and treatment of this rare and aggressive cancer.
The Office of Cancer Genomics (OCG), along with the Office of HIV and AIDS Malignancies (OHAM), initiated the HIV+ Tumor Molecular Characterization Project (HTMCP) to gain insight into the genetic events driving HIV-associated cancers and to determine why certain cancers, but not others, have higher incidences in HIV-positive patients.
CGCI developed the Medulloblastoma Project to apply newly emerging genomic methods towards the discovery of novel genetic alterations in medulloblastoma (MB).
Non-Hodgkin Lymphoma- Complete
CGCI initiated the Non-Hodgkin Lymphoma Project to elucidate the mutation spectrums of the two most abundant forms of non-Hodgkin lymphoma (NHL)Opens in a New Tab: follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).